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Abstract 
Background: Previous studies showed that atherosclerotic plaque vulnerability was related with 
microparticles (MPs)-vesicles larger than 100 nm, which released MMP9 collagenase. In our pre-
vious study, intramuscular injection of a new drug (PTCTS) normalized oxidized LDL serum levels 
and reduced rabbit atherosclerosis. Now, we studied administration of oral PTCTS in order to cla-
rify anti-atherosclerotic mechanism of action, analyzing if the treatment removed MPs containing 
ox-LDL and Mycoplasma pneumoniae antigens and improved the immune response. Methods: We 
compared two groups of rabbits. Control group (CG, n = 6)—1% cholesterol enriched diet for 12 
weeks; Treated group (TG, n = 8)—1% cholesterol enriched diet for 12 weeks with administration 
of PTCTS (400 μl/day) during the last 6 weeks of diet. The animals had their blood collected, in 
three different phases of the protocol before being fed with hypercholesterolemic diet, before be-
ing treated with water or PTCTS and at the moment of sacrifice. The serum was submitted to im-
munofluorescence technique to evaluate the quantity of microparticles marked with antibodies 
against Mycoplasma pneumoniae and ox-LDL. A fragment of aorta was submitted to immunohisto-
chemical detection of antigens from MMP9, ox-LDL, NF-κB and IL-1β. Results: PTCTS showed sig-
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nificant reduction in MMP-9 (P = 0.001) and a tendency of reducing IL-1β (P = 0.09) in the aortic 
plaques compared with CG. In the serum, PTCTS was able to remove microparticles containing an-
tigen of ox-LDL (P = 0.004) and Mycoplasma pneumoniae (P < 0.001). Conclusion: Oral treatment 
with PTCTS presented more adequate inflammatory response by reducing levels of ox-LDL, IL-1β 
and mycoplasma, as well as a better stabilization of the atheromatous plaque by reducing levels of 
MMP-9, avoiding plaque rupture, without causing mortality or toxicity. 
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1. Introduction 
Atherosclerosis is a chronic inflammatory disease that affects medium and large sized arteries [1] resulting in 
the formation of fatty and fibrous lesions in the vessel wall. Atherogenesis is marked by inflammatory processes 
in all its stages, from early endothelial activation by modified lipids to eventual rupture of the atherosclerotic 
plaque [2] [3]. 
The first steps in atherosclerosis are the modification of LDL into oxidized LDL (ox-LDL) microparticles, 
leading to a local inflammation with the release of chemotactic factors and expression of adhesion molecules on 
the surface of endothelial cells, attraction of monocytes and development of atherosclerotic lesion [4].  
The initial inflammatory response in atherosclerosis may be considered an attempt to eliminate potentially 
harmful ox-LDL microparticles, which has been related to the development of atherosclerosis [5]. Ox-LDL can 
enhance activation of endothelial cells, and short-term incubation or usage of low concentrations of ox-LDL can 
also enhance nuclear factor kappa-B (NF-κB) activation in monocytes [6]. 
As a transcription factor in inflammatory responses, NF-κB is involved in the regulation of inflammatory and 
immune genes, apoptosis, and cell proliferation [7]. The activation of NF-κB in endothelial cells during early 
atherogenesis or in other cells during later stages may occur by many different stimuli [8], including minimally 
ox-LDL [9] or infectious agents such as chlamydia [10] and mycoplasma [11].  
Another activator of the NF-κB pathway in atherogenesis is IL-1β, a pro-inflammatory cytokine released in 
the lesion site that may affect atherosclerosis by regulating many other NF-κB dependent genes and amplify the 
inflammatory response [12]. 
A major factor involved in monocyte-to-macrophage differentiation is macrophage colony-stimulating factor 
(M-CSF), which is regulated by NF-κB [13]. For optimal migration of monocyte/macrophages into tissues, de-
gradation of extracellular matrix is a requirement. A crucial enzyme in this process is the matrix metalloprotei-
nase-9 (MMP-9), whose transcription is also regulated by NF-κB [14]. In addition to mediating macrophage in-
filtration, MMP-9 also facilitates smooth muscle cell migration [15] that may contribute to the fibrotic cap for-
mation leading to a stabilization of the atheroma plaque. On the other hand, increased levels of MMP-9 are in-
volved in degradation of this fibrous cap and segmental vessel dilatation, favoring plaque rupture [16] [17] and 
development of aneurysms [18]. In both situations, human studies from our lab found increased amount of mi-
croorganisms such as Mycoplasma pneumoniae and Chlamydophila pneumoniae [19], as well as activation of 
toll like receptors (TLR) 2 and 4 [20]. Antigens from Mycoplasma pneumoniae and oxLDL were found in in-
creased levels in microparticles present in vulnerable plaques [21]. 
Particulated transialidase (PTCTS) is a compound containing transialidase from Trypanosoma cruzi from re-
combinant bacteria diluted 10,000× in thermal water and extract of orchid, whose method and production are 
protected by granted US patents (US7335638B2, US7674832B2 and US7906114B2), with INCI name approved 
for cosmetics gel that presents anti-aging and anti-oxidative activities [22] produced by Higuchi & Santos 
Ciência e Biotecnologia Ltda. 
For oral administration, PTCTS is associated with nanoparticles from Allivium sativus, Ginkgo biloba and 
Zingiber officinalis, whose methods and production are also protected by US patents (US7335638B2, US 
7732410 and US7914781) diluted 1:10,000×. In previous study, this compound, injected intramuscularly, had 
anti-atherosclerotic effect in rabbits [23].  
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Now, we studied if PTCTS’ anti-atherosclerotic mechanism of action is linked with removal of microparticles 
containing ox-LDL and Mycoplasma pneumoniae antigens and improvement in immune response through 
NF-κB and IL-1β action. 
2. Methods 
2.1. Experimental Design 
We fed two groups of New Zealand rabbits, from the Central Bioterium of Medical School of University of São 
Paulo, aging approximately 60 days and weighing 2.2 ± 0.5 kg with 1% cholesterol enhanced diet for 12 weeks 
in order to induce the atherosclerotic process. The group used as control (CG n = 6, 3 male) was treated with 
drops of water, while the treated group had oral administration of PTCTS (400 µL/day) during the last 6 weeks 
of diet as treatment (TG n = 8, 4 male).  
Based on previous pilot studies, with different concentrations of PTCTS compounds, we set a dose of 400 µL/ 
day as the best one, and decided to treat the rabbits during the same period it takes to completely develop the 
atherosclerotic process (6 weeks). Thus, the rabbits were fed with hypercholesterolemic diet for 12 weeks and 
treated with PTCTS for the last 6 weeks. 
The study was developed according to the “Guide for the Care and Use of Laboratory Animals”—US Nation-
al Institutes of Health (NIH Publication No. 85-23, revised 1996) and approved by the Ethics Committee of the 
University of Sao Paulo (USP). 
2.2. Sample Collection 
The animals had their blood collected, from the ear marginal vein, in three different phases of the protocol: 1) 
Before being fed with hypercholesterolemic diet, which values were used as normal control; 2) After being fed 
with hypercholesterolemic diet and before being treated with water (CG) or PTCTS (TG); 3) At the end of the 
experiment during the sacrifice, after the rabbits received their treatment. 
The animals were sacrificed after 12 weeks of the protocol by previous injection of anesthetics (ketamine 25 - 
50 mg/kg associated to xylazin 2 - 5 mg/kg via intramuscular) that had their action boosted with intra-cardiac 
barbituric (Tiopental) and potassium chloride 3 mL. A fragment of aorta was dissected at its root and harvested 
in 10% buffered formalin for analysis. Macroscopic and microscopic exams of main organs were performed in 
order to evaluate toxicity. 
2.3. Immunohistochemistry 
The resected fragments were processed and paraffin-embedded. Serial sections of 5 μm were submitted to immu-
nohistochemical detection of MMP-9 antigens (56-2A4-Abcam), ox-LDL (clone 2C7OSF10, prepared and donated 
by Dr. DulcinéiaAbdalla [24]), NF-κB (polyclonal-Biorbyt), and IL-1β (polyclonal-Cloud-Clone Corp).  
Antigen retrieval was performed with 0.15% Trypsin or buffers (Tris-EDTA 10mM pH 9.0 or Citrate 10mM 
pH 6.0) in a pressure cooker (Pascal, DakoCytomation, USA). The blocking of endogenous peroxidase was per-
formed with 6% H2O2, at room temperature (RT). Next, sections were incubated with a Background Suppression 
Reagent (CAS-Block™, Invitrogen) for 10 min, RT. Primary antibodies were incubated for 40 min, RT. For the 
detection of the complex antigen/antibody, Picture Max HRP kit (Invitrogen) was used. Staining procedure was 
completed using diaminobenzidine chromogen (DAB, Dako Cytomation) and counter-staining with Har-
ris-hematoxylin. The highest point of atherosclerotic plaque was evaluated in 0,5mm extension of histological 
ascendant aorta cross section and evaluated at ImageScope Software (Version 11.2.0.780, Aperio Technologies) 
by colorimetric differentiation. 
2.4. Immunofluorescence 
We used the immunofluorescence technique to evaluate the quantity of microparticles in the serum marked with 
primary antibodies against Mycoplasma pneumoniae (Mp)-(clone B748M, Abcam), and ox-LDL (clone 
2C7scFv prepared and donated by Dr. Dulcinéia Abdalla).  
The serum was incubated with primary antibodies for 1 h at 25˚C. After this period, we added the secondary 
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antibody: Alexa Fluor 488-Invitrogen, for ox-LDL and Alexa Fluor 555-Invitrogen, for Mp and incubated for 
another hour at 25˚C. 
We photographed 4 pictures for all the animals at Evos fluorescence microscope (×20). Each picture had the 
particles counted in two opposite fields of 0.023 mm2 at IrfanView (version 4.35, Irfan Skilijan) software, total-
ing 8 fields/animal. We calculated the mean of these values for statistical analysis. 
2.5. Statistics 
All data are disposed as mean ± SD. We used T test to compare the data from CG and TG. For Immunofluores-
cence we compared the serum from samples 2 and 3 in animals of the same group through paired T test, and 
used the difference of values from the serum of sample 2 and 3 (ΔT) to verify the real difference in number of 
particles from the groups when correlated with the data obtained from immunohistochemistry by Pearson’s 
Correlation test. All statistical tests were performed at SigmaStat (version 3.5, Systat) software. 
3. Results 
PTCTS did not cause mortality or presented any level of toxicity in the organs evaluated. 
3.1. Immunohistochemistry 
Immunohistochemistry evaluation showed that there was a reduction of some inflammatory markers level in 
treated group when compared with control group. Treatment with PTCTS lead to a significant reduction of 
MMP-9 in aorta of rabbits (P = 0.001) (Figure 1), and a tendency of the same effect on IL-1β (P = 0.09), while 
the others inflammatory markers presented no difference. 
3.2. Immunofluorescence 
Comparison of the serum collected in phase pre-treatment (2) between the groups demonstrated that both anti-
gens had the same behavior with no significant difference: ox-LDL - CG2: 302.83 ± 239.58, TG2: 327.62 ± 
89.16, P = 0.81; Mp - CG2: 285.67 ± 105.86, TG2: 234.62 ± 192.41, P = 0.57. But when the serum of phase 
post-treatment (3) was compared, the group treated with PTCTS showed a significant reduction in the quantity 
of ox-LDL (CG3: 417.17 ± 220.6, TG3: 190.87 ± 55.4, P = 0.01) as well as in Mp (CG3: 437.5 ± 198.99, TG3: 
132.6298.6, P = 0.003) (Figure 2). 
The comparison of ΔT of the groups revealed that PTCTS was able to significantly remove particles marked 
with ox-LDL (CTΔT: 111.33 ± 267.25, TGΔT: −136.75 ± 111.12, P = 0.004) and Mp (CGΔT: 151.83 ± 112.45, 
TGΔT: −102 ± 100.8, P < 0.001). 
 
 
Figure 1. Photomicrograph of cross-section’s detail of aorta in immunohisto-
chemistry. In the left side, a sample of control group (CG) strongly marked with 
anti-MMP-9 antibody in the plaque (brown color, purple arrow), while treated 
group (TG) represented on the right side presented weak marking with anti- 
MMP-9 antibody (orange arrow). Magnification, ×8. 
S. M. Garavelo et al. 
 
 111 
 
Figure 2. Immunofluorescence fields analyzed. Difference in the quantity of particles marked with anti-ox-LDL and Mp an-
tibodies pre and post treatment. Control group (CG) presented high amount of particles marked with anti-ox-LDL antibody 
(A) as well as treated group (TG) before the treatment with PTCTS (B). After the treatment, TG demonstrated a significant 
reduction in particles marked with anti-ox-LDL antibody in serum (C). The same effect was noticed against antigens of my-
coplasma. CG presented a high amount of particles marked with anti-Mp antibody (D) as well as treated group (TG) before 
the treatment with PTCTS (E). After the treatment, TG demonstrated a significant reduction in particles marked with an-
ti-Mp antibody in serum (F). Magnification ×20. 
3.3. Correlations 
We correlated the values obtained from immunohistochemistry with the ones from immunofluorescence in order 
to understand how the inflammatory process developed in the two different groups.  
The results showed that in CG NF-κB correlated weakly with MMP-9 (r = 0.77 P = 0.07) and negatively with 
particles marked with Mp in the serum (r = −0.71 P = 0.11). There was no other correlation in control group. 
In the other hand, in group TG, NF-κB correlated negatively with MMP-9 (r = −0.84 P = 0.03) and weakly 
with ox-LDL in the plaque (r = −0.78 P = 0.06), there was weak correlations of MMP-9 with ox-LDL in the 
plaque (r = 0.65 P = 0.16) and of the ox-LDL present in the plaque with the ox-LDL in the serum (r = 0.68 P = 
0.14). IL-1β correlated weakly with both of the antigens marked in the serum: positively with ox-LDL (r = 0.67 
P = 0.14) and negatively with Mp (r = −0.62 P = 0.18). 
4. Discussion 
Inflammatory response is a normal physiological reaction of the body to restore and maintain homeostasis [24]. 
Innate immune system mechanisms of defense are activated to kill and remove most of the harmful substances. 
The innate and the adaptive immune response, although often viewed as separated systems, are intertwined and 
affect each other [25].  
PTCTS organic nanoparticles would work as exogenous anti-oxidant benign exosomes and the transialidase 
would detach mycoplasmas by removing sialic acid from their main sites and releasing them to act as ligand of 
the siglecs components family. 
Mycoplasmas are among the few prokaryotes that can grow almost “symbiotically” and have a close interac-
tion with mammalian host cells for long periods of time [26], these bacteria are able to synthesize lipoproteins as 
MALP-404, a large lipoprotein previously described by Wise’s laboratory as P41. Derived from MALP-404, 
MALP-2, a macrophage activating lipopeptide of about 2kDa mol. (Figure 3), is responsible for the compara-
tively much higher activity of the mycoplasmal product [27] by inducing the response of cytokines, chemokines 
and prostaglandins by activated macrophage.  
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Besides all the mycoplasma’s effects when in human body, apparently they also exert both apoptotic and an-
ti-apoptotic effects, respectively promoting internucleosomal DNA fragmentation, induction of a number of 
pro-inflammatory cytokines production and activation of NF-κB, or by activation of resting murine and human 
lymphocytes, inducing their proliferation, on mammalian cells [28]. 
Several studies demonstrated that mycoplasmas can activate NF-κB through different pathways. Mycoplasma 
may be recognized by TLR2 and TLR6 [29] through MALP-2, leading to the activation of NF-κB and resulting 
in the synthesis of pro-inflammatory cytokines TNF-α, IL-1β and IL-6 [30] (Figure 4).  
NF-κB binding sites B are present in lots of cytokines genes, including TNF-a, IL-6 and IL-1β [31] [32]. 
 
 
Figure 3. Structure of synthetic MALP-2.               
 
 
Figure 4. TLR-2, TLR-6, recognize MALP-2 from mycoplasma membrane, recruit 
adaptor protein MyD88 and activate common upstream activator (IRAK/TRAF6 
and TAK1) of NF-B and MAPK. Activated NF-κB and MAPK translocate to the 
nucleus and bind to their motifs (NF-κB, AP-1) in the promoter of target genes (in-
cluding early-response and inflammatory genes) and induce their transcription into 
mRNA which will ultimately lead to increased cytokine production. p38 MAPK al-
so involved posttranscriptional regulation of pro-inflammatory genes by modulation 
of mRNA stability in the cytoplasm. (TLR: toll-like receptor, MyD88: myeloid dif-
ferentiation primary response gene 88; IRAK: interleukin-1 receptor-associated ki-
nase; TRAF6: TNF receptor associated factor 6; TAK1: TGF-beta activated kinase 
1; ERK: extracellular signal-regulated kinase: JNK: c-Jun N-terminal kinase). 
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Once PTCTS is administrated orally, we could notice its first actions in the blood, with significant reduction in 
the numbers of circulating microparticles containing antigens of ox-LDL and micoplasma. 
Oral treatment with PTCTS did not decrease significantly the levels of NF-κB in the tissue, but once it re-
duced the presence of mycoplasma, the activation of NF-κB through MALP-2 pathway was also reduced. This 
decrease may have contributed to the lower levels of IL-1β in the tissue, represented by the negative correlation 
with Mp and positively with ox-LDL, both in the serum.  
PTCTS also lead to a lower expression of MMP-9, demonstrated by the negative correlation of the collage-
nase with NF-κB. 
The negative correlation of NK-κB and ox-LDL in the plaque could mean that once the immune response is 
going back to its normal, the reduction of ox-LDL was still not visible in the tissue, but as soon as the immune 
response stabilize the treatment would present better effects in this site too. All these data suggest that a longer 
period of treatment with PTCTS and/or adjustments in its admixture could reduce the inflammation in the tissue 
to levels that belong to a normal, not an exacerbated immune response by reducing two of the most important 
agents that contribute to the development of atherosclerosis: ox-LDL and pathogenic microorganisms, Mycop-
lasma pneumoniae in this case; as well as act with the stabilization of the atheromatous plaque by reducing the 
presence of MMP-9 in the tissue.  
These data suggest that PTCTS acts in the control the exacerbated inflammation and in the stabilization of the 
plaque. 
5. Conclusion 
Rabbits treated with oral PTCTS presented an improvement in the inflammatory response by reducing levels of 
ox-LDL, IL-1β and mycoplasma, as well as a better stabilization of the atheromatous plaque by reducing levels 
of MMP-9, avoiding plaque rupture, without causing mortality or toxicity. 
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